1. Home
  2. IKT vs KEQU Comparison

IKT vs KEQU Comparison

Compare IKT & KEQU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IKT
  • KEQU
  • Stock Information
  • Founded
  • IKT 2008
  • KEQU 1906
  • Country
  • IKT United States
  • KEQU United States
  • Employees
  • IKT N/A
  • KEQU N/A
  • Industry
  • IKT Biotechnology: Pharmaceutical Preparations
  • KEQU Medical Specialities
  • Sector
  • IKT Health Care
  • KEQU Industrials
  • Exchange
  • IKT Nasdaq
  • KEQU Nasdaq
  • Market Cap
  • IKT 140.5M
  • KEQU 158.3M
  • IPO Year
  • IKT 2020
  • KEQU N/A
  • Fundamental
  • Price
  • IKT $1.66
  • KEQU $54.80
  • Analyst Decision
  • IKT Buy
  • KEQU
  • Analyst Count
  • IKT 2
  • KEQU 0
  • Target Price
  • IKT $8.00
  • KEQU N/A
  • AVG Volume (30 Days)
  • IKT 97.5K
  • KEQU 6.7K
  • Earning Date
  • IKT 08-14-2025
  • KEQU 09-10-2025
  • Dividend Yield
  • IKT N/A
  • KEQU N/A
  • EPS Growth
  • IKT N/A
  • KEQU N/A
  • EPS
  • IKT N/A
  • KEQU 3.83
  • Revenue
  • IKT N/A
  • KEQU $240,472,000.00
  • Revenue This Year
  • IKT N/A
  • KEQU N/A
  • Revenue Next Year
  • IKT N/A
  • KEQU N/A
  • P/E Ratio
  • IKT N/A
  • KEQU $14.03
  • Revenue Growth
  • IKT N/A
  • KEQU 18.02
  • 52 Week Low
  • IKT $1.12
  • KEQU $30.33
  • 52 Week High
  • IKT $4.20
  • KEQU $71.33
  • Technical
  • Relative Strength Index (RSI)
  • IKT 45.73
  • KEQU 47.71
  • Support Level
  • IKT $1.66
  • KEQU $53.50
  • Resistance Level
  • IKT $1.87
  • KEQU $58.95
  • Average True Range (ATR)
  • IKT 0.10
  • KEQU 1.59
  • MACD
  • IKT -0.01
  • KEQU -0.37
  • Stochastic Oscillator
  • IKT 33.82
  • KEQU 17.59

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

About KEQU Kewaunee Scientific Corporation

Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.

Share on Social Networks: